Molecular insight into the T798M gatekeeper mutation-caused acquired resistance to tyrosine kinase inhibitors in ErbB2-positive breast cancer.
Lu, Ji; Zhou, Kun; Yin, Xiaoxing; Xu, Han; Ma, Baojin.
Comput Biol Chem
; 78: 290-296, 2019 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-30605854
[Impact of the response of primary tumor to preoperative chemotherapy and anti-HER2 therapy on survival of HER2-positive breast cancer patients].
Portable detection of serum HER-2 in breast cancer by a pressure-based platform.
Inhibitor Response to HER2 G776(YVMA) In-frame Insertion in HER2-positive Breast Cancer.
Her2 assessment using quantitative reverse transcriptase polymerase chain reaction reliably identifies Her2 overexpression without amplification in breast cancer cases.
A systematic analysis of the resistance and sensitivity of HER2YVMA receptor tyrosine kinase mutant to tyrosine kinase inhibitors in HER2-positive lung cancer.
Coamplification of protects -amplified breast cancers from targeted therapy.
Less is more? De-intensification of therapy for early-stage HER2-positive breast cancer.
Safety Analysis of Premenopausal Breast Cancer Patients in PALOMA-3 Study: Is It Worth Mentioning?
Response to "Do metastasis-free interval less or more than 24 months for recurrent metastatic breast cancer and primary surgery for de novo metastatic breast cancer matter for survival?"
Biosimilar Therapy for ERBB2 (HER2)-Positive Breast Cancer: Close Enough?